Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.

Mazumder, Anika; Darji, Kavita; Smith, Kristin; Guo, Mary

Mazumder, Anika; Darji, Kavita; Smith, Kristin; Guo, Mary.

Afiliación

Mazumder A; Saint Louis University School of Medicine, Saint Louis, Missouri, USA anika.mazumder@health.slu.edu.
Darji K; Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Smith K; Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
Guo M; Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.

BMJ Case Rep ; 15(12)2022 Dec 07.

Article en En | MEDLINE | ID: mdl-36593610

Asunto(s)

Nivolumab; Penfigoide Ampolloso; Humanos; Nivolumab/efectos adversos; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Penfigoide Ampolloso/inducido químicamente; Penfigoide Ampolloso/tratamiento farmacológico; Anticuerpos Monoclonales Humanizados/uso terapéutico

Palabras clave

Cancer intervention; Dermatology; Oncology; Unwanted effects / adverse reactions

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Penfigoide Ampolloso / Nivolumab Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: BMJ Case Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google